Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma: translating CARES-009 outcomes into a new therapeutic paradigm.

AiTan (rivoceranib) - Elevar Therapeutics

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/42254167

Asra Amjad; Fazila Niaz Hashmi; Mebin Job; Muddassir Khalid; Muhammad Junaid; Saaim Sikandar; Umair Ali; Zoona Maryam

Jun 9, 2026